Methods and compositions for the diagnosis and prognosis of Alzheimer's disease
View Patent ↗The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.
1. An assay comprising the steps of:
contacting a sample of a peripheral biological fluid obtained from a patient suffering from Alzheimer's disease with a probe capable of binding specifically to L-selectin, wherein the peripheral biological fluid is serum or plasma;
measuring the concentration of L-selectin from the sample specifically bound to the probe; and
providing the measured concentration of L-selectin specifically bound to the probe.
2. The assay of claim 1 , wherein the probe capable of binding specifically to L-selectin is an antibody.
3. The assay of claim 2 , wherein the antibody is a monoclonal antibody.
4. The assay of claim 2 , wherein the antibody is a polyclonal antibody.
5. The assay of claim 1 , further comprising the steps of:
contacting the sample with a probe capable of binding specifically to a known biomarker of Alzheimer's disease;
measuring the concentration of the known biomarker of Alzheimer's disease from the sample specifically bound to the probe; and
providing the measured concentration of the known biomarker of Alzheimer's disease specifically bound to the probe.
6. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-1α.
7. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-1β.
8. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-8.
9. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IFN-γ.
10. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is VEGF.
11. The assay of claim 1 , wherein the peripheral biological fluid is serum.
12. The assay of claim 1 , wherein the peripheral biological fluid is plasma.
13. The assay of claim 1 , wherein the patient suffering from Alzheimer's disease has accelerated cognitive decline (ACD).
14. The assay of claim 1 , wherein the patient suffering from Alzheimer's disease has slow cognitive decline (SCD).